Company profile
Home | MirZyme Therapeutics
MirZyme Therapeutics is an innovative biopharmaceutical company that focuses on the ......
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNzE3NTI2MWFkaXF6a2N4
Published 25 Sep 2024 10:36
Company registered at Companies House
MirZyme Therapeutics is an innovative biopharmaceutical company that focuses on the development and commercialisation of diagnostics and drugs for women with pregnancy complications, specifically preeclampsia.
Inward investment from UK, China and Malaysia.
1 Nov 2023 to 31 Oct 2024
Preeclampsia is a hypertensive disease of pregnancy that kills over 500,000 infants each year and for which there are currently no approved prophylactic or therapeutic treatments. Current management options are inadequate as it involves delivering the baby by Caesarean section, regardless of gestational maturity. Our studies show that preeclampsia is a 'd...
